LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Kodu・Aktsiate loetelu・Puma Biotechnology Inc

Puma Biotechnology Inc

Suletud

SektorTervishoid

6.8 -2.58

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

6.77

Max

7.03

Põhinäitajad
By Trading Economics
Sissetulek	-16M -3.8M
Müük	-31M 45M
P/E Sektori keskmine	14.833 49.888
Aktsiakasum	-0.04
Kasumimarginaal	-8.375
Töötajad	179
EBITDA	-28M -1.3M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-28.37% downside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-21M 362M
Eelmine avamishind	9.38
Eelmine sulgemishind	6.8

Puma Biotechnology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. juuni 2026, 23:22 UTC

Tulu

Suurimad hinnamuutused turgudel

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3. juuni 2026, 23:09 UTC

Kuumad aktsiad

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3. juuni 2026, 20:51 UTC

Tulu

Costco Reports 15% Sales Growth in May

3. juuni 2026, 20:43 UTC

Tulu

Broadcom 2Q Revenue Climbs on AI Chip Demand

3. juuni 2026, 23:48 UTC

Market Talk

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3. juuni 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. juuni 2026, 23:35 UTC

Market Talk

Oil Futures Fall on Possible Technical Correction -- Market Talk

3. juuni 2026, 23:15 UTC

Market Talk

Tulu

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3. juuni 2026, 22:08 UTC

Kuumad aktsiad

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3. juuni 2026, 21:54 UTC

Market Talk

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3. juuni 2026, 21:18 UTC

Tulu

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3. juuni 2026, 21:15 UTC

Tulu

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3. juuni 2026, 21:13 UTC

Tulu

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3. juuni 2026, 21:13 UTC

Tulu

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3. juuni 2026, 21:12 UTC

Tulu

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3. juuni 2026, 21:09 UTC

Tulu

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3. juuni 2026, 21:03 UTC

Tulu

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3. juuni 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. juuni 2026, 20:43 UTC

Tulu

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3. juuni 2026, 20:39 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3. juuni 2026, 20:37 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3. juuni 2026, 20:35 UTC

Tulu

Broadcom Stock Falls Despite Record Results -- Barrons.com

3. juuni 2026, 20:21 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3. juuni 2026, 20:17 UTC

Tulu

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3. juuni 2026, 20:17 UTC

Tulu

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3. juuni 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3. juuni 2026, 20:15 UTC

Tulu

Broadcom 2Q Adj EPS $2.44 >AVGO

3. juuni 2026, 20:15 UTC

Tulu

Broadcom 2Q EPS $1.91 >AVGO

3. juuni 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3. juuni 2026, 20:15 UTC

Tulu

Broadcom 2Q Rev $22.19B >AVGO

Võrdlus sarnastega

Hinnamuutus

Puma Biotechnology Inc Prognoos

Hinnasiht

By TipRanks

-28.37% langus

12 kuu keskmine prognoos

Keskmine 5 USD -28.37%

Kõrge 5 USD

Madal 5 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Puma Biotechnology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Puma Biotechnology Inc aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.